NCT07016516View on ClinicalTrials.gov

A Study to Learn About PRT-064040 Nasal Spray in Healthy Adult Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 7, 2025

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions
Migraine
Interventions
DRUG

PRT-064040 nasal spray

A single dose of PRT-064040 nasal spray at one of six dose levels

DRUG

Placebo

A single dose of Placebo at one of six dose levels

DRUG

PRT-064040 nasal spray

Multiple doses of PRT-064040 nasal spray at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days

DRUG

Placebo

Multiple doses of Placebo at one of two dose levels, administered once daily (QD) for a total of 7 consecutive days

Trial Locations (1)

Unknown

RECRUITING

The Third Hospital of Changsha, Changsha

All Listed Sponsors
lead

Sichuan Purity Pharmaceutical Technology Co., Ltd.

INDUSTRY